证券时报•数据宝统计，华检医疗在港交所公告显示，11月25日以每股6.140港元至6.290港元的价格回购 85.60万股，回购金额达535.32万港元。该股当日收盘价6.290港元，下跌1.41%，全天成交额1787.90万 港元。 自11月21日以来公司已连续3日进行回购，合计回购331.30万股，累计回购金额2035.15万港元。 其间该 股累计上涨7.52%。 今年以来该股累计进行27次回购，合计回购1930.90万股，累计回购金额1.03亿港元。（数据宝） 华检医疗回购明细 | 日期 | 回购股数 | 回购最高价 | 回购最低价 | 回购金额 | | --- | --- | --- | --- | --- | | | （万股） | （港元） | （港元） | （万港元） | | 2025.11.25 | 85.60 | 6.290 | 6.140 | 535.32 | | 2025.11.24 | 202.70 | 6.240 | 5.700 | 1247.24 | | 2025.11.21 | 43.00 | 6.000 | 5.630 | 252.59 | | 2025.11.18 | 131. ...

智通财经APP讯，华检医疗(01931)发布公告，于2025年11月25日斥资535.3万港元回购85.6万股。 ...

华检医疗(01931)发布公告，于2025年11月25日斥资535.3万港元回购85.6万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 華檢醫療控股有限公司 呈交日期： 2025年11月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01931 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有 ...

Core Viewpoint - The control change plan of Chuangye Huikang (300451.SZ) has emerged, with founder Ge Hang transferring the largest shareholder position to Hangzhou Genghao Investment Management Partnership (Limited Partnership) for 500 million yuan, aiming to restructure the board and gain actual control [1][2]. Group 1: Control Change Details - The control change involves a "transfer agreement + voting rights entrustment" approach, where Ge Hang will transfer 96.52 million shares (6.23% of total shares) to Hangzhou Genghao at a price of 5.18 yuan per share, totaling 500 million yuan [2]. - After the transfer, Hangzhou Genghao will control 12.64% of the voting rights through entrusted voting rights, becoming the largest shareholder of Chuangye Huikang [2][3]. - The board will be restructured to include four non-independent directors and two independent directors nominated by Hangzhou Genghao, resulting in a total of 11 board members [2]. Group 2: Financial and Operational Challenges - Chuangye Huikang is facing significant financial difficulties, with a revenue decline of 26.26% year-on-year to 862 million yuan in the first nine months of 2025, and a net profit drop of 331.69% to -122 million yuan [9][10]. - The company has accumulated 1.643 billion yuan in accounts receivable, nearly double its revenue, which is straining cash flow and operational efficiency [10]. - The company has been consistently recognizing credit impairment and asset impairment provisions, with significant amounts recorded in the first three quarters of 2025 [10]. Group 3: Strategic Intentions and Market Outlook - Hangzhou Genghao aims to leverage the acquisition to achieve financial consolidation and accelerate business development, capitalizing on the growing "AI + healthcare" market [7][9]. - Despite the operational challenges, Chuangye Huikang's stock price has shown an upward trend since the announcement of the control change, indicating market optimism about potential recovery through the acquisition [11].

Summary of Key Points Core Viewpoint - A total of 36 companies conducted share buybacks on November 24, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 1.022 million shares for a total of 636 million yuan, representing 0.825% of its total share capital for the year [1][2]. - China COSCO Shipping (01919) repurchased 3 million shares for 40.35 million yuan, accounting for 1.604% of its total share capital [2]. - China International Marine Containers (02039) repurchased 4.8904 million shares for 35.9467 million yuan, which is 1.530% of its total share capital [2]. Group 2: Other Notable Buybacks - China Feihe (06186) repurchased 7.233 million shares for 29.9668 million yuan, representing 1.969% of its total share capital [2]. - Sinopec Limited (00386) repurchased 4.054 million shares for 17.7861 million yuan, which is 0.150% of its total share capital [2]. - Pacific Basin Shipping (02343) repurchased 5 million shares for 12.757 million yuan, accounting for 1.555% of its total share capital [2]. Group 3: Smaller Buybacks - MONGOL MINING (00975) repurchased 390,000 shares for 3.6551 million yuan, which is 0.124% of its total share capital [2]. - Miniso Group (09896) repurchased 866,800 shares for 31.938 million yuan, representing 0.372% of its total share capital [2]. - Weigao Group (01066) repurchased 40,000 shares for 211,600 yuan, accounting for 4.379% of its total share capital [3].

华检医疗(01931)发布公告，于2025年11月24日斥资1247.24万港元回购202.7万股股份。 ...

智通财经APP讯，华检医疗(01931)发布公告，于2025年11月24日斥资1247.24万港元回购202.7万股股 份。 ...

格隆汇11月24日丨华检医疗(01931.HK)公告，11月24日耗资1247万港元回购202.7万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 華檢醫療控股有限公司 呈交日期： 2025年11月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01931 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫 ...